Amgen disclosed Tuesday that its experimental biologic dazodalibep achieved the primary goal of its late‑stage trial, delivering a statistically significant and clinically meaningful reduction in disease activity for patients with Sjogren’s disease. The results, presented at a forthcoming medical conference, mark a notable milestone for a condition that currently has no approved therapies in the United States.
Key trial outcomes
The Phase III study evaluated dazodalibep in adults diagnosed with Sjogren’s disease, an autoimmune disorder that attacks the body’s moisture‑producing glands, leading to severe dryness of the eyes, mouth, and other tissues, as well as fatigue and chronic pain. At week 48, participants receiving the drug demonstrated a clear improvement in disease activity scores compared with baseline, meeting the trial’s predefined statistical thresholds.
Adverse events were generally mild to moderate. Only a small number of participants discontinued treatment due to side effects, suggesting a tolerable safety profile for the investigational therapy.
Broader context
Sjogren’s disease affects about 1% of the global population and predominantly impacts women, according to the National Institutes of Health. Despite its prevalence, the disease has long lacked an FDA‑approved treatment, leaving patients to manage symptoms with supportive care alone.
Amgen’s announcement comes as other major pharmaceutical companies, including Novartis and Johnson & Johnson, are also pursuing drug candidates for Sjogren’s disease. The competitive landscape underscores the growing recognition of unmet medical needs in autoimmune disorders.
Next steps for dazodalibep
Amgen plans to present detailed efficacy and safety data from the trial at an upcoming medical meeting later this year. The company expects to complete the trial’s final data collection in the fourth quarter of 2026 and will then engage with regulatory authorities to discuss potential pathways for approval.
Should the drug receive approval, it would provide the first disease‑modifying option for millions of patients worldwide, offering relief from the debilitating dryness, pain, and fatigue that characterize Sjogren’s disease.
Industry reaction
Industry analysts noted that the positive trial results could bolster Amgen’s pipeline in the autoimmune space and strengthen its position against rivals developing similar therapies. While the final regulatory outcome remains uncertain, the data represent a promising step toward addressing a significant therapeutic gap.
Patients, advocacy groups, and clinicians alike have expressed optimism that a new treatment option may soon become available, potentially improving quality of life for those living with this chronic condition.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
